HYLAN G-F 20

Summary

Hylan G-F 20 (CHEMBL4297767) is a phase-3 clinical-stage unknown; indicated across 3 conditions including osteoarthritis, hip and osteoarthritis, knee.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297767
Name	HYLAN G-F 20
Type	Unknown
Max phase	3

Also known as: Hyaluronic acid crosslinked, Hyaluronic acid, crosslinked, Hylan g-f 20, Synvisc, HYLAN G-F 20

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis, hip	3	MONDO:0006629	EFO:1000786
osteoarthritis, knee	3	MONDO:0005416	EFO:0004616
patellofemoral pain syndrome	2	MONDO:0006894	EFO:1001092

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE4	7
PHASE3	5
Not specified	3
PHASE1	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01557868	PHASE4	COMPLETED	Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis
NCT01586338	PHASE4	COMPLETED	A Study of the Efficacy and Safety of Synvisc® in Chinese Subjects With Symptomatic Osteoarthritis of the Knee(s)
NCT01874574	PHASE4	COMPLETED	Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee
NCT02197026	PHASE4	COMPLETED	Effectiveness and Safety of Synvisc® Versus Usual Treatments in Patients With Knee Osteoarthritis
NCT03090698	PHASE4	UNKNOWN	Outcomes of Injections in Patients Waiting for Total Knee Replacement
NCT03484091	PHASE4	COMPLETED	Comparison of Single Intra-articular Injection of Hyruan-One With Hylan G-F 20 in Knee Osteoarthritis
NCT03694821	PHASE4	TERMINATED	Knee Injection RCT
NCT00131352	PHASE3	COMPLETED	A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee
NCT00325845	PHASE3	UNKNOWN	Synvisc Injections for Lumbar Facet Joint Pain
NCT02694146	PHASE3	COMPLETED	Clinical Trial to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis
NCT04019782	PHASE3	UNKNOWN	Collagen-PVP vs Hylan G-F 20 in the Treatment of Knee Osteoarthritis
NCT04333160	PHASE3	COMPLETED	Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis
NCT02613247	PHASE2	UNKNOWN	Intra-articular Hyaluronic Acid Injection for Therapy-resistant Patellofemoral Pain Syndrome
NCT00949494	PHASE1	COMPLETED	Effects of Synvisc on Cartilage in Knee Osteoarthritis (OA)
NCT01810848	PHASE1	TERMINATED	Pilot Study of Therapy With Hylan G-F 20 Exercise Capacity
NCT05727371	Not specified	ACTIVE_NOT_RECRUITING	Combination of PRP and XLHA Prepared With RegenMatrix Medical Device To Treat Moderate to Severe Knee Osteoarthritis
NCT00147186	Not specified	UNKNOWN	The Effectiveness of Hylan GF-20 on Joint Reaction Forces and Kinematic Patterns During Gait in Patients With Knee Osteoarthritis
NCT00971074	Not specified	WITHDRAWN	Study of Viscosupplementation for the Treatment of Knee Pain After Menisectomy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).